1. Home
  2. BRN vs PHGE Comparison

BRN vs PHGE Comparison

Compare BRN & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Barnwell Industries Inc.

BRN

Barnwell Industries Inc.

HOLD

Current Price

$1.09

Market Cap

12.2M

Sector

Energy

ML Signal

HOLD

Logo BiomX Inc. COmmon Stock

PHGE

BiomX Inc. COmmon Stock

HOLD

Current Price

$2.36

Market Cap

6.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BRN
PHGE
Founded
1956
2015
Country
United States
Israel
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.2M
6.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
BRN
PHGE
Price
$1.09
$2.36
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$26.00
AVG Volume (30 Days)
45.2K
124.8K
Earning Date
12-17-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$18,073,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.05
$2.28
52 Week High
$2.28
$22.06

Technical Indicators

Market Signals
Indicator
BRN
PHGE
Relative Strength Index (RSI) 42.09 48.79
Support Level $1.05 $2.31
Resistance Level $1.16 $2.85
Average True Range (ATR) 0.05 0.59
MACD -0.01 -0.22
Stochastic Oscillator 13.64 35.00

Price Performance

Historical Comparison
BRN
PHGE

About BRN Barnwell Industries Inc.

Barnwell Industries Inc is an oil and gas firm. Its areas of operations include acquiring, developing, producing, and selling oil and natural gas. The company acquires and develops crude oil and natural gas assets. The company's operating segment includes Oil and natural gas, Contract drilling, Land investment, and Others. It generates maximum revenue from the Oil and natural gas segment. It operates in two geographical segments the United States, which generates a majority of revenue, and Canada.

About PHGE BiomX Inc. COmmon Stock

BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).

Share on Social Networks: